XML 14 R4.htm IDEA: XBRL DOCUMENT v3.19.1
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Net revenues $ 4,295 $ 5,065
Cost of sales 2,440 2,750
Gross profit 1,856 2,315
Research and development expenses 261 317
Selling and marketing expenses 648 738
General and administrative expenses 292 329
Intangible assets impairment 469 206
Goodwill impairment   180
Other assets impairments, restructuring and other items 1 501
Legal settlements and loss contingencies 57 (1,278)
Other income (6) (203)
Operating income 134 1,525
Financial expenses, net 218 271
Income (loss) before income taxes (84) 1,254
Income taxes 9 46
Share in losses of associated companies, net 4 74
Net income (loss) (97) 1,134
Net income attributable to non-controlling interests 8 14
Net income (loss) attributable to Teva (105) 1,120
Dividends on preferred shares   65
Net income (loss) attributable to ordinary shareholders $ (105) $ 1,055
Earnings (loss) per share attributable to ordinary shareholders:    
Basic $ (0.10) $ 1.04
Diluted $ (0.10) $ 1.03
Weighted average number of shares (in millions):    
Basic 1,090 1,017
Diluted 1,090 1,020